Beyond the headline. Into the evidence.

The study, simply explained. More than 20,000 people completed stool tests (Cologuard Plus and FIT) and also had a colonoscopy to check what was present. Cologuard Plus tested positive in 93.9% of people with cancer and 43.4% of those with advanced precancer. Cologuard Plus detected more than FIT stool testing but also produced more false-positive results.

Keep in view. One Cologuard Plus screening round, among people who already had the specified finding. These are detection rates, not future cancers prevented or the chance of disease after a negative result. BLUE-C and the FDA entries analyze overlapping evidence, not three independent studies.

Funding & disclosures. Funded by Exact Sciences; multiple authors were Exact Sciences employees.

• BLUE-C · Published Cologuard Plus accuracy study · primary source

The study, simply explained. In the FDA analysis, Cologuard Plus tested positive in 81 of 85 people with cancer (95.3%) and 849 of 1,962 with advanced precancer (43.3%) in one screening round.

Keep in view. One screening round among people who already had cancer or advanced precancer. The FDA analysis uses a different participant set from the publication: keep 95.3% / 43.3% together, and 93.9% / 43.4% together. This does not establish lifetime prevention or imply colonoscopy finds every lesion.

Funding & disclosures. Regulatory source; the underlying pivotal study was sponsored by Exact Sciences.

• FDA · Cologuard Plus primary-effectiveness analysis · primary source
• Manufacturer claim
• BLUE-C

The study, simply explained. Of 16,414 people with a negative Cologuard Plus result, 1,113 still had advanced precancer on colonoscopy: 6.8%, or about 1 in 15.

Keep in view. The denominator is people with a negative result, not everyone with advanced precancer. These are one-round estimates from this study population, not an individual’s personal risk or future protection. A negative stool result does not automatically mean immediate colonoscopy is needed.

Funding & disclosures. Regulatory source; the underlying pivotal study was sponsored by Exact Sciences.

• FDA · What a negative Cologuard Plus result can still contain · primary source
• Manufacturer claim
• NCI: prevention through polyp removal

Simply explained. Colonoscopy lets a physician visually examine the inside of the colon and remove detected polyps during the same procedure. Removing precancerous polyps can prevent colorectal cancer. Stool tests look for warning signs in a stool sample; a positive result needs colonoscopy.

Keep in view. Colonoscopy can miss lesions and has preparation, sedation, bleeding, perforation, and other burdens or risks. Some growths require a separate removal procedure. Stool-based screening can also lead to polyp removal after a positive result is followed by colonoscopy.

Funding & disclosures. U.S. government source.

• NCI · What colonoscopy can do · primary source

The study, simply explained. Reviewers for the U.S. Preventive Services Task Force pooled studies covering more than 5 million screening colonoscopies. They estimated about 3 perforations (a tear in the colon) and about 15 major bleeds for every 10,000 procedures. Put another way, roughly 9,980 of every 10,000 screening colonoscopies had neither.

Keep in view. These are pooled estimates; individual risk varies with age, health, and whether a polyp is removed. Sedation carries its own risks. The same review estimated somewhat higher rates when colonoscopy follows an abnormal stool test: about 5 perforations and 17.5 serious bleeds per 10,000.

Funding & disclosures. Evidence review prepared for the U.S. Preventive Services Task Force with federal funding (Agency for Healthcare Research and Quality).

• Lin et al. · USPSTF evidence report, JAMA 2021 · primary source
• USPSTF evidence summary

The study, simply explained. Researchers followed 2,602 people after precancerous polyps were removed. Over a median of nearly 16 years, 12 died from colorectal cancer, compared with about 25 expected from general-population rates: 53% fewer deaths than expected.

Keep in view. Observational comparison with expected population mortality, with subsequent follow-up care.

Funding & disclosures. Supported by the National Cancer Institute and others; see the publication’s disclosures.

• National Polyp Study · Zauber et al. · primary source

The study, simply explained. Researchers randomly assigned adults to receive a colonoscopy invitation or usual care. Only 42% of those invited attended. After 13 years, colorectal-cancer risk was 1.46% in the invited group versus 1.80% in the other group, a 19% relative reduction. A reduction in colorectal-cancer deaths was not statistically established.

Keep in view. The randomized result measures an invitation to screening, including people who did not attend. It is not the measured benefit of completing colonoscopy. A statistically significant reduction in colorectal-cancer deaths was not established, and Cologuard was not a comparator.

Funding & disclosures. Public/charitable funding; some investigators disclosed endoscopy-industry relationships.

• NordICC · Randomized trial, 13-year results · primary source

The study, simply explained. Researchers followed nearly 89,000 health professionals for up to 22 years. People who had screening colonoscopy had a 68% lower colorectal-cancer death rate after statistical adjustment than people who had no screening colonoscopy. The study observed people's care; it did not randomly assign tests.

Keep in view. Observational, not randomized. Health behaviors and other differences between people who did and did not undergo screening may influence the association. This was not a comparison with Cologuard.

Funding & disclosures. Funded by the National Institutes of Health and others; see the authors’ disclosures.

• U.S. health-professional cohorts · Nishihara et al. · primary source

The study, simply explained. A German study followed about 9,200 adults for a median of 17 years. Screening colonoscopy was associated with 56% fewer colorectal cancers and a 66% lower colorectal-cancer death rate after adjustment. The associations were clearer in the lower colon and rectum than in the upper colon.

Keep in view. Observational evidence cannot establish causation by itself. Associations were stronger in the lower colon and rectum; upper-colon estimates were less certain. This was not a comparison with Cologuard.

Funding & disclosures. Funding and conflict details are not provided in the indexed abstract used by the current review; consult the full publication.

• German prospective cohort · Guo et al. · primary source

The study, simply explained. Across three U.S. cohorts, researchers compared 81,151 people whose screening colonoscopy found no polyps or cancer with 114,302 people without endoscopy. The negative-colonoscopy group had lower colorectal-cancer and cancer-death rates, with lower cancer risk still seen through 20 years.

Keep in view. Observational cohorts with limitations in generalizability and examination-quality information. This does not tell an individual to wait 20 years for the next exam. Follow-up depends on findings, examination quality, family history, and clinical guidance. A negative-exam study does not isolate the effect of polyp removal.

Funding & disclosures. Public and charitable funding; some authors reported outside industry relationships. Full disclosures accompany the article.

• Negative screening colonoscopy · Knudsen et al. · primary source

Simply explained. The American Cancer Society recommends that average risk adults start colon cancer screening at age 45. Colonoscopy and stool-based tests are among the recommended options. A positive stool test needs timely follow-up colonoscopy.

Keep in view. This is screening guidance, not a head-to-head prevention trial. ACS does not rank colonoscopy above stool-based tests. Our preference for colonoscopy applies to people who are medically appropriate, willing, and have timely access; other recommended screening plans remain valid.

Funding & disclosures. Guideline evidence synthesis; conflicts disclosed in the publication.

• ACS screening recommendations · 2026 · primary source
• ACS explanation

The study, simply explained. Researchers used hypothetical choices to predict screening preferences. Stool DNA had the largest predicted share among patients (39.4%); colonoscopy had the largest share among physicians (95.0%). Only physicians’ choice tasks included how well tests find precancerous polyps.

Keep in view. Hypothetical, modeled preferences, not completed screening or doctors’ own screening choices. The patient model’s 39.4% leading share was not a majority. Patients and physicians differed in training and experience as well as the information shown; this was not a randomized test of education.

Funding & disclosures. Exact Sciences sponsored the research; company-affiliated authors participated and disclosed stock or stock options. The 2025 predictions reuse a 2020–2021 survey. Full disclosures accompany the publications.

• NCI screening information
• USPSTF recommendation
• Fendrick 2025: updated predictions
• Heidenreich 2022: original experiment

The study, simply explained. A Spanish trial invited people to one colonoscopy or FIT every two years, with colonoscopy after a positive FIT. More participated in the FIT group. At ten years, colorectal-cancer deaths were uncommon in both groups (0.24% with FIT; 0.22% with colonoscopy), and FIT met the trial’s preset standard for not being meaningfully worse.

Keep in view. FIT is a stool-blood test, not multitarget stool DNA. This was invitation/program-level evidence with colonoscopy follow-up. The trial supports repeated FIT; the uncommon mortality endpoint does not negate its prespecified noninferiority result. A later adjusted sustained-strategy analysis also found similar incidence, so participation differences alone do not explain away the findings.

Funding & disclosures. Funded by Fundación Científica de la Asociación Española contra el Cáncer and Instituto de Salud Carlos III.

• COLONPREV · Repeated FIT versus colonoscopy invitations · primary source
• Randomized trial
• Sustained-strategy analysis

The study, simply explained. Kaiser expanded organized screening, mainly annual FIT and colonoscopy, with outreach and follow-up. From 2000 to 2015, the proportion up to date with screening rose from 38.9% to 82.7%. Over the same period, colorectal-cancer rates fell 25.5% and colorectal-cancer death rates fell 52.4%.

Keep in view. Before-and-after observational study, not a randomized comparison. Other changes over time may have contributed. It studied an organized FIT-and-colonoscopy program, not Cologuard or one isolated test.

Funding & disclosures. Research support reported in the publication.

• Kaiser Permanente · Organized screening · primary source
• Kaiser study

The study, simply explained. A conference review pooled studies of colonoscopy findings. At least one adenoma, a common type of potentially precancerous polyp, was found in an estimated 66.3% of colonoscopies after a positive stool-DNA test, versus 33.8% of initial screening colonoscopies. The first group had already been selected by a positive test.

Keep in view. Conference abstract only, with substantial differences among included studies. This is post-positive colonoscopy yield, not stool-test sensitivity. It counted any adenoma, not just advanced precancer, and excluded people who did not complete colonoscopy.

Funding & disclosures. Research funded by Exact Sciences.

• ASCO abstract · Polyps found after a positive stool-DNA test · primary source
• Geographic-access research and its limitations

The study, simply explained. A computer model compared stool-DNA testing every three years with one colonoscopy over ten years. Its main scenario assumed more people would complete stool testing and projected fewer cancer deaths with that strategy. However, when everyone completed the screening and follow-up, the model instead projected a larger reduction in deaths with colonoscopy: 52% versus 43% compared with no screening.

Keep in view. Computer projections, not observed deaths in a ten-year clinical trial. Main assumptions and other sensitivity scenarios favored stool DNA; the perfect-adherence scenario favored colonoscopy. The result depends on the model and its assumptions, not just the test’s capabilities.

Funding & disclosures. Five authors list Exact Sciences affiliations. Consult the publication for the full funding and conflict disclosures.

• Dore 2026 · Repeated stool DNA versus one colonoscopy · primary source

The study, simply explained. Three independent research teams built computer models of screening for the Task Force. For colonoscopy every 10 years from age 45 to 75, they estimated 301 to 369 years of life gained for every 1,000 people screened. Yearly stool-test strategies landed in a similar range, on one condition: every test is done on schedule and every positive result is followed by a colonoscopy. No model found stool DNA testing every three years to be an efficient strategy compared with other stool-based options.

Keep in view. These are model projections, not observed outcomes. The Task Force recommends several screening options and does not rank them. The models also count the burdens of colonoscopy, including complications, and real-world completion differs for every test.

Funding & disclosures. Modeling prepared for the U.S. Preventive Services Task Force with federal funding; see the publication for full funding and disclosures.

• Knudsen et al. · USPSTF modeling study, JAMA 2021 · primary source
• USPSTF modeling report

The study, simply explained. Researchers modeled screening with a fixed number of colonoscopy appointments. When appointments were limited, stool testing left more capacity for follow-up after positive results. With more total capacity, the model allocated a larger share to primary screening colonoscopy: 20% at 15 million annual exams, 35% at 18 million, and 63% at 30 million.

Keep in view. A population model of one screening episode, not observed individual outcomes or a repeated lifetime program. The 20%, 35%, and 63% figures are shares of all colonoscopy capacity allocated to primary screening, not percentages of patients screened.

Funding & disclosures. Exact Sciences funded and participated in the study; four authors were employees/stockholders.

• Fendrick 2026 · Allocating colonoscopy capacity · primary source

Simply explained. The 2024 ASGE/ACG guidance tells practices what to measure: polyp detection, adequate preparation, examination completion, and appropriate follow-up. These are tools for improving care, not a guarantee that any one examination will find everything.

Keep in view. These are quality-improvement recommendations, not individual test-sensitivity figures, credentialing rules, or a guarantee that any examination will find everything.

Funding & disclosures. See the primary publication or guidance for funding and conflict disclosures.

• Read the ASGE/ACG guidance

The study, simply explained. Researchers followed patients after 485,615 colonoscopies in Poland. Among doctors who had lower precancer detection rates, improving their detection rate was linked to fewer colorectal cancers later. The same clear improvement-related difference was not found among doctors who already had higher detection rates.

Keep in view. Observational association. The same clear improvement-related difference was not found among physicians starting at higher detection rates. The study’s 26% dividing point is not a recommended quality target or an individual test-sensitivity estimate.

Funding & disclosures. Authors disclosed public research grants and outside endoscopy-industry relationships; see individual disclosures in the publication.

• Pilonis et al. · Better detection and later cancer risk · primary source

The study, simply explained. A review of 36 studies covering more than 3.5 million colonoscopies found that gastroenterologists, as a group, had higher adenoma-detection and examination-completion rates than surgeons. The studies varied substantially, and the overall evidence was rated low certainty.

Keep in view. Mostly observational evidence, substantial study differences, and low overall certainty. These group averages do not rank individual doctors or establish that specialty itself caused the differences.

Funding & disclosures. See the primary publication or guidance for funding and conflict disclosures.

• Mazurek et al. · Primary publication

The study, simply explained. A review of 27 studies covering about 11.3 million colonoscopies found that doctors doing more procedures each year were more likely to complete the examination. Higher volume was not linked to better adenoma detection, and it did not consistently predict fewer cancers after colonoscopy.

Keep in view. Observational evidence, with limited information about doctors performing fewer than 100 procedures a year. A lack of detected association does not establish that experience is irrelevant.

Funding & disclosures. See the primary publication or guidance for funding and conflict disclosures.

• Forbes et al. · Primary publication

The study, simply explained. Researchers studied colonoscopies performed after positive FIT results in Korea's national screening program. Doctors with fewer recorded procedures had higher rates of colorectal cancer diagnosed within a year after an examination that had not found cancer.

Keep in view. Observational study of FIT-positive patients in Korea, not a direct comparison of individual U.S. doctors. Program-recorded counts do not necessarily capture the physician’s full workload or provide a universal minimum procedure count.

Funding & disclosures. See the primary publication or guidance for funding and conflict disclosures.

• Kim et al. · Primary publication

The study, simply explained. In a randomized trial of 2,032 patients, doctors used either standard colonoscopy or colonoscopy with GI Genius AI assistance. At least one adenoma was found in 56.6% of patients with AI versus 48.4% without it. The study measured detection, not later cancer prevention.

Keep in view. Adenoma detection rate counts examinations finding at least one adenoma; it is not the proportion of all precancers detected and cannot be compared directly with stool-test sensitivity. Added long-term cancer prevention remains unproven, and trials and guidelines have not all reached the same conclusion.

Funding & disclosures. COLO-DETECT and the additional CADILLAC trial were funded by Medtronic. Guidance documents have their own disclosures.

• Read COLO-DETECT
• Read CADILLAC
• AGA guideline
• ESGE position statement

Simply explained. Selected 2024 quality-improvement targets include adenoma detection ≥35%, sessile serrated lesion detection ≥6%, adequate preparation ≥90%, cecal intubation ≥95%, and average withdrawal time ≥8 minutes in eligible normal examinations without biopsy or polyp removal.

Keep in view. Detection and withdrawal measures apply to eligible patients aged 45 or older. Exclusions include positive non-colonoscopy screening tests, inflammatory bowel disease, genetic cancer syndromes, and therapy of known neoplasms. Read the source for complete definitions. These are not individual timing guarantees, test sensitivity, or credentialing standards.

Funding & disclosures. Professional quality guidance; see the source for contributor disclosures.

• Definitions and targets · Tables 2–3

The study, simply explained. U.S. cancer-registry data show colorectal cancer diagnoses rising among younger adults. From 2013 to 2022, incidence at ages 20–49 grew about 3% a year. Adults aged 45–49 account for about half of diagnoses before age 50.

Keep in view. These are population trends and shares of diagnoses, not a visitor’s personal risk or evidence of which test is best. Some recent increase reflects screening finding existing cancers; more advanced cancers also increased. Symptoms or higher-risk history may require evaluation earlier.

Funding & disclosures. Authors were ACS employees, paid from ACS funds, and declared no conflicts. ACS receives foundation grants, including health-sector-linked grants, for other work; these authors were not funded by or key personnel on those grants.

• Read Siegel et al., 2026

The study, simply explained. Researchers examined cancer-registry data covering 45.8% of the U.S. population from 2000 through 2023. After a long decline, the overall colorectal cancer diagnosis rate increased from 36.7 to 38.3 cases per 100,000 people between 2022 and 2023, after adjusting for differences in age. Recent increases extended through ages 65–69, a group that previously experienced substantial declines. Published October 27, 2026, the report describes diagnoses through 2023; further years of data are needed to establish whether the overall increase persists.

What this study does NOT show. It did not compare colonoscopy with Cologuard, determine which screening test is best, or establish that either test caused the changing cancer rates. It did not measure trends in advanced precancer or establish a need to change recommended screening ages or intervals.

Keep in view. An increase in diagnoses does not necessarily mean an equally large increase in newly developing disease. The authors suggest that increased screening likely contributed to the sharp rise in diagnoses among adults aged 45–49 by finding cancers already present. Pandemic disruptions may also have influenced the trends, although the authors considered catch-up diagnoses unlikely to fully explain the 2023 increase. This is population surveillance, not a prediction of any individual’s risk.

Funding & disclosures. Supported in part by the National Institutes of Health and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Program. Individual author disclosures are provided separately by the journal; those forms were not independently reviewed.

• Murphy et al. · Colorectal Cancer among U.S. Adults, 2000–2023 · primary report
• Burus & Semprini · Age and stage trends after screening expansion

Murphy review added November 1, 2026. Full report reviewed; supplementary tables and individual disclosure forms were not independently reviewed.

The study, simply explained. Researchers analyzed nearly 490,000 colorectal cancer diagnoses and compared patterns across generations. After accounting for age and calendar period, their model found higher risk in generations born after about 1950. The often-quoted 'double' and 'quadruple' figures compare the roughly 1990 and 1950 birth groups.

Keep in view. Modeled relative comparisons, not observed lifetime risks or a personal forecast. The youngest generations had limited follow-up and less precise estimates. The study does not compare screening tests.

Funding & disclosures. Supported by the ACS Intramural Research Department and NIH/NCI Intramural Research program. The paper reports no funder role in study conduct or publication. No separate author conflict statement was identified in the article; this is not a declaration that no conflicts exist.

• Read Siegel et al., 2017

Simply explained. CMS Quality ID #113 / CMS130v14. A colorectal-cancer screening process measure in which multiple accepted screening methods can satisfy the numerator when performed within their specified intervals.

Keep in view. Measure credit is not a ranking of test capabilities or a guarantee that follow-up is complete. A positive stool test still needs colonoscopy.

Funding & disclosures. Official measure specification; see the issuing organization’s disclosures and terms.

• Official CMS130v14 specification
• 2026 Quality ID #113 specification

Simply explained. A widely used performance measure that counts multiple accepted colorectal-cancer screening methods, including stool DNA testing and colonoscopy.

Keep in view. NCQA describes HEDIS as a performance-measurement tool, not a clinical guideline or endorsement of a particular test.

Funding & disclosures. Official measure specification; see the issuing organization’s disclosures and terms.

• Official NCQA colorectal-cancer screening measure
• NCQA’s HEDIS disclaimer